COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,441 Articles (22,835 medRxiv, 8,606 bioRxiv)

Most recent first Previous |  Page 1248: Articles 12471-12480  | Next

Efficacy of SARS-CoV-2 wastewater surveillance for detection of COVID-19 at a residential private college
Landstrom, M., Braun, E., Larson, E., Miller, M., Holm, G. H.
10.1101/2021.09.15.21263338 — Posted: 2021-09-22
Real-world clinical performance of SARS-CoV-2 point-of-care diagnostic tests: a systematic review of available trials as per April, 4, 2021
Hawthorne, G. H., Harvey, A.
10.1101/2021.09.20.21263509 — Posted: 2021-09-22
Vitamin D and socioeconomic deprivation mediate COVID-19 ethnic health disparities
Marino-Ramirez, L., Ahmad, M., Rishishwar, L., Nagar, S. D., Lee, K. K., Norris, E. T., Jordan, I. K. K.
10.1101/2021.09.20.21263865 — Posted: 2021-09-22
Long Term Accuracy of SARS-CoV-2 Interferon-γ Release Assay and its Application in Household Investigation
Murugesan, K., Jagannathan, P., Altamirano, J., Maldonado, Y. A., Bonilla, H. F., Jacobson, K. B., Parsonnet, J., Andrews, J. R., Shi, R.-Z., Boyd, S., Pinsky, B. A., Singh, U., Banaei, N.
10.1101/2021.09.20.21263527 — Posted: 2021-09-22
HUMORAL AND CELLULAR IMMUNOGENICITY and SAFETY UP TO 4 MONTHS AFTER VACCINATION WITH BNT162B2 mRNA COVID-19 VACCINE IN HEART AND LUNG TRANSPLANTED YOUNG ADULTS
Cotugno, N., Pighi, C., Morrocchi, E., Ruggiero, A., Amodio, D., Medri, C., Colagrossi, L., Di Cesare, S., Santilli, V., Manno, E. C., Zangari, P., Giancotta, C., Bernardi, S., Nicolosi, L., Ciofi degli Atti, M., Raponi, M., Zaffina, S., Alfieri, S., Kirk, R., Perno, C. F., Rossi, P., Convers Study Team, , Amodeo, A., Palma, P.
10.1101/2021.09.20.21263836 — Posted: 2021-09-22
Viral loads and profile of the patients infected with SARS-CoV-2 Delta, Alpha or R.1 variants in Tokyo
Tani-Sassa, C., Iwasaki, Y., Ichimura, N., Nagano, K., Takatsuki, Y., Yuasa, S., Takahashi, Y., Nakajima, J., Sonobe, K., Nukui, Y., Takeuchi, H., Tanimoto, K., Tanaka, Y., Kimura, A., Tohda, S.
10.1101/2021.09.21.21263879 — Posted: 2021-09-22 Discussion: Onsite
Epidemiology, clinical presentation and management of COVID-19 associated Mucormycosis: A single center experience from Pune, Western India.
Dravid, A., Kashiva, R., Khan, Z., Bande, B., Memon, D., Kodre, A., Potdar, P., Mane, M., Tamboli, A., Pawar, V., Patil, D., Banerjee, D., Bhoite, K., Shinde, A., Pharande, R., Kalyani, S., Raut, P., Bapte, M., Saldanha, C., Chandak, D., Ajani, F., Mehta, A., Reddy, M. S., Bhayani, K., S S, L., P D, V., Srivastava, S., Khandelwal, S., More, S., Shakeel, A., Pawar, M., Nande, P., Harshe, A., Kadam, S., Halikar, S., Kamal, N., Andrabi, D., Bodhale, S., Raut, A., Gawande, P., Bhandari, A., Wasmatkar, N., Sarkar, A., Chandrashekhar, S., Butiyani, P., Akhade, G., Abnave, A., Raman, C., Basade, S., Mahajan, U., Joshi, G., Mane, D.
10.1101/2021.09.15.21263622 — Posted: 2021-09-22
mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?
Wijtvliet, V. P. W. M., Arien, K. K., Abrams, S., Couttenye, M. M., Mestrez, F., Marien, J., De Winter, B. Y., Van Damme, P., Pipeleers, L., Wissing, K. M., Abramowicz, D., Ledeganck, K.
10.1101/2021.09.15.21263320 — Posted: 2021-09-22
Virological and Serological Characterization of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination.
Colavita, F., Meschi, S., Gruber, C. E. M., Rueca, M., Vairo, F., Matusali, G., Lapa, D., Giombini, E., De Carli, G., Spaziante, M., Messina, F., Bonfiglio, G., Carletti, F., Lalle, E., Fabeni, L., Berno, G., Puro, V., Di Caro, A., Bartolini, B., Ippolito, G., Capobianchi, M. R., Castilletti, C., INMI Covid-19 laboratory surveillance team
10.1101/2021.09.21.21263882 — Posted: 2021-09-22
University patenting and licensing practices in the United Kingdom during the COVID-19 pandemic - implications for global equitable access to COVID-19 health technologies
Keestra, S. M., Rodgers, F., Osborne, R., Wimmer, S.
10.1101/2021.09.20.21263777 — Posted: 2021-09-22

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).